Ameriprise Financial Inc Tcr2 Therapeutics Inc. Transaction History

Ameriprise Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$16.41 - $24.71 $295,297 - $444,656	-17,995 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $713 - $1,192	35 Added 0.19%	17,995 $398,000
Q4 2020 Feb 12, 2021	BUY	$19.0 - $32.63 $23,370 - $40,134	1,230 Added 7.35%	17,960 $556,000
Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $54,430 - $85,966	4,155 Added 33.04%	16,730 $340,000
Q2 2020 Aug 14, 2020	SELL	$6.51 - $16.85 $166,395 - $430,686	-25,560 Reduced 67.03%	12,575 $193,000

Q1 2020 May 15, 2020	SELL	$6.01 - $16.01 $6,490 - $17,290	-1,080 Reduced 2.75%	38,135 $295,000
Q4 2019 Feb 14, 2020	SELL	$12.17 - $17.88 $16,977 - $24,942	-1,395 Reduced 3.44%	39,215 $560,000
Q3 2019 Nov 14, 2019	SELL	$10.15 - $19.53 $811,898 - $1.56 Million	-79,990 Reduced 66.33%	40,610 $610,000
Q2 2019 Aug 14, 2019	SELL	$13.64 - $20.97 $234,553 - $360,600	-17,196 Reduced 12.48%	120,600 $1.73 Million
Q1 2019 May 15, 2019	BUY	$15.01 - $22.15 $2.07 Million - $3.05 Million	137,796 New	137,796 $2.4 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.